These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

717 related items for PubMed ID: 17552951

  • 1. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
    Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S.
    BJU Int; 2007 Jul; 100(1):33-6. PubMed ID: 17552951
    [Abstract] [Full Text] [Related]

  • 2. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H.
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [Abstract] [Full Text] [Related]

  • 3. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E, Iborra I, Rubio J, Casanova J, Almenar S.
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [Abstract] [Full Text] [Related]

  • 4. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 5. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
    Huguet J, Gaya JM, Sabaté S, Palou J, Villavicencio H.
    Actas Urol Esp; 2010 Jan; 34(1):63-70. PubMed ID: 20223134
    [Abstract] [Full Text] [Related]

  • 6. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, Zietman AL.
    BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
    [Abstract] [Full Text] [Related]

  • 7. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, Shinohara N, Oya M, Miki T, Cancer Registration Committee of the Japanese Urological Association.
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [Abstract] [Full Text] [Related]

  • 8. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
    Margel D, Tal R, Golan S, Kedar D, Engelstein D, Baniel J.
    Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
    [Abstract] [Full Text] [Related]

  • 9. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, Wong WS, Lai FM, To KF, Li ML.
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [Abstract] [Full Text] [Related]

  • 10. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 11. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED.
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [Abstract] [Full Text] [Related]

  • 12. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M.
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [Abstract] [Full Text] [Related]

  • 13. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
    Nieder AM, Simon MA, Kim SS, Manoharan M, Soloway MS.
    Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564
    [Abstract] [Full Text] [Related]

  • 14. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
    Pham HT, Soloway MS.
    Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
    [Abstract] [Full Text] [Related]

  • 15. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder.
    Zhang GK, Uke ET, Sharer WC, Borkon WD, Bernstein SM.
    J Urol; 1996 Jun; 155(6):1907-9. PubMed ID: 8618284
    [Abstract] [Full Text] [Related]

  • 16. Pathological upstaging during radical cystectomy is associated with worse recurrence-free survival in patients with bacillus Calmette-Guerin-refractory bladder cancer.
    Guzzo TJ, Magheli A, Bivalacqua TJ, Nielsen ME, Attenello FJ, Schoenberg MP, Gonzalgo ML.
    Urology; 2009 Dec; 74(6):1276-80. PubMed ID: 19758684
    [Abstract] [Full Text] [Related]

  • 17. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P, Holmäng S.
    BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
    [Abstract] [Full Text] [Related]

  • 18. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
    Boudreaux KJ, Clark PE, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Chang SS.
    J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment.
    Okamura T, Akita H, Imura M, Kaneko T, Mizuno K, Tozawa K, Kohri K.
    Int J Urol; 2008 Oct; 15(11):976-80. PubMed ID: 18721199
    [Abstract] [Full Text] [Related]

  • 20. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A, Yonou H, Hayashi E, Iha K, Oda M, Miyazato M, Oshiro Y, Hokama S, Sugaya K, Ogawa Y.
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.